N/A N=10 Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade
Schizophrenia
Primary: Working Memory — 44.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 HIV Non Occupational Post-Exposure Prophylaxis (PEP)
HIV Infections
Primary: Medication Regimen Completion Rates — 57; 28; 15 participants
Phase 2 N=19 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response Rates (Complete and Partial) Evaluated Using RECIST Criteria — 2 participants
N/A N=132 A South African Pilot Worksite Parenting Program to Prevent HIV Among Adolescents
Parent-Child Relations
Primary: Number of Topics Discussed Between Parent and Child — 8.3; 7.8; 9.4; 7.2 number of sex and HIV topics discussed
Phase 4 N=751 Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B
Chronic Hepatitis B
Primary: Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone…
Phase 3 N=10 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
Transthyretin Familial Amyloid Polyneuropathy
Primary: Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay — 10 Participants
Phase 2 N=37 Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage III Renal Cell Cancer
Primary: Progression-free Survival Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) (Phase II) — 48.6 percent
Phase 3 N=439 A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Multiple Sclerosis
Primary: Time to Confirmed Disease Progression (CDP) — NA; NA weeks — p=0.1442
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
N/A N=22 Treating Co-Morbid Sleep Difficulties in Veterans With Posttraumatic Stress Disorder (PTSD): A Pilot Study
Posttraumatic Stress Disorder · Insomnia
Primary: Insomnia Severity — 21.58; 12.45 ISI Score
Phase 2 N=55 Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Phase 2 N=34 Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
Healthy Volunteers
Primary: Area Under the Curve of Plasma Naproxen From 0 to t — 67763.0; 69427.9 min×μg/mL
Phase 2 N=31 Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Phase 1 N=60 Antihypertensive Treatment in Acute Cerebral Hemorrhage
Intracerebral Hemorrhage · Hypertension · Stroke
Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01
Phase 3 N=208 Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Sickle Cell Disease
Primary: Hospital Length of Stay (Hours) — 56; 47 hours — p=0.24